Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lineage Cell TherapeuticsLCTX -2.65%79 Cash Ratio is 6.34 as of Jun. 2026, which is 79% above its 10-year median of 3.54. GuruFocus rates LCTX with a GF Score™ of 79/100 and a GF Value™ of $1.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,383 Biotechnology companies, Lineage Cell Therapeutics ranks better than 69.85% on this metric.
Lineage Cell Therapeutics has a Cash Ratio of 6.34. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Lineage Cell Therapeutics's Cash Ratio or its related term are showing as below:
LCTX'
s Cash Ratio Range Over the Past 10 Years
Min: 1.17 Med: 3.54 Max: 10.16
Current: 6.55
During the past 13 years, Lineage Cell Therapeutics's highest Cash Ratio was 10.16. The lowest was 1.17. And the median was 3.54.
LCTX's Cash Ratio is ranked better than 69.85% of 1383
companies
in the Biotechnology industry
Industry Median: 2.93
vs LCTX: 6.55
Lineage Cell Therapeutics (AMEX:LCTX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lineage Cell Therapeutics Cash Ratio Related Terms
Lineage Cell Therapeutics Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lineage Cell Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (LCTX) has a Cash Ratio of 6.34 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lineage Cell Therapeutics and its competitors. This is 79% above median its historical median of 3.54. Over the past decade, Lineage Cell Therapeutics' Cash Ratio has ranged from 1.17 to 10.16. According to the industry distribution chart, Lineage Cell Therapeutics ranks #417 out of 1383 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Lineage Cell Therapeutics' Cash Ratio too high?
Lineage Cell Therapeutics' current Cash Ratio of 6.34 is 79% above median its 10-year median of 3.54. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 10.16. The Biotechnology industry median Cash Ratio is 2.93. Lineage Cell Therapeutics' value of 6.34 is 116.4% above this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #417 out of 1383 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lineage Cell Therapeutics has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Cash Ratio compare to NAGE and IFRX?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #417 out of 1383 companies for Cash Ratio. This puts Lineage Cell Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.93. Lineage Cell Therapeutics' value of 6.34 is 116.4% above this benchmark. Historically, Lineage Cell Therapeutics' own Cash Ratio has ranged from 1.17 to 10.16 over the past decade. While the company's 10-year median is 3.54 vs. the industry median of 2.93, Lineage Cell Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current Cash Ratio of 6.34 is 116.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current Cash Ratio is 6.34, which is 79% above median its own 10-year median of 3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.31, compared to a current price of $1.10 — trading 16% below its estimated fair value. The current Cash Ratio is 6.34, which is 79% above median its 10-year median of 3.54 and 116.4% above the Biotechnology industry median of 2.93. Lineage Cell Therapeutics' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Cash Ratio is 6.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.10 is trading 16% below its estimated GF Value™ of $1.31.
GuruFocus considers Lineage Cell Therapeutics to be Modestly Undervalued.
Key valuation signals for LCTX:
Cash Ratio: 6.34 (79% above median its 10-year median of 3.54)
GF Value™: $1.31 vs. price of $1.10 (16% below fair value)
Industry Position: 116.4% above the Biotechnology median (#417 of 1383)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
79GF Score
Get the complete analysis for LCTX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
